Skip to main content

Lung Cancer

Ensartinib may be a viable treatment option for some forms of secondary ALK alterations. Read More ›

Similar progression-free survival and 2-year overall survival rates reported for both treatment groups, with more grade ≥3 treatment-related adverse events reported in the afatinib + cetuximab group. Read More ›

Study evaluated the benefits of afatinib in Asian and non-Asian patients who had not received EGFR-TKI therapy for their EGFR-mutant NSCLC. Read More ›

Patients with untreated advanced NSCLC with EGFR mutations achieved improved progression-free survival with treatment with gefitinib and carboplatin plus pemetrexed compared with gefitinib alone. Read More ›

Researchers report higher overall response rate, median duration of response, and median progression-free survival in treatment-naïve patients with a MET exon 14 skipping mutation compared with previously treated patients. Read More ›

Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations. Read More ›

Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease. Read More ›

Overall response rate, duration of response, and media progression-free survival were highest in the group of treatment-naïve patients with T790M negativity and any MET mutation. Read More ›

Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums. Read More ›

Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study. Read More ›

Page 3 of 10